Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04037397 · ClinicalTrials.gov registry record · Phase 3
First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)
A Phase 3 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT04037397: Completed Phase 3 study, sponsored by University of Pennsylvania.
NCT04037397 is a Phase 3 study that has completed, run by University of Pennsylvania. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04037397, a Phase 3 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if catheter-based atrial fibrillation (AF) ablation is superior to treatment with antiarrhythmic drugs as a first-line therapy for symptomatic persistent AF.
Interventions
- DRUG Anti Arrhythmics
- PROCEDURE Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04037397
The ClinicalTrials.gov registry entry for NCT04037397 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anti Arrhythmics is the first listed.
NCT04037397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04037397 about?
NCT04037397 is a clinical study titled "First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)". The purpose of this study is to determine if catheter-based atrial fibrillation (AF) ablation is superior to treatment with antiarrhythmic drugs as a first-line therapy for symptomatic persistent AF.
What is the current status of trial NCT04037397?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2019-09-24. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT04037397?
The interventions under investigation include: Anti Arrhythmics (DRUG), Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation (PROCEDURE).
Who is sponsoring clinical trial NCT04037397?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.